Friday, September 22, 2023
Clinical Advances in
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a potentially fatal autoimmune condition characterized by damage to, and inflammation of, small blood vessels commonly in the kidneys, respiratory tract or the skin. Current treatment for AAV consists of various therapies that have not been studied in placebo-controlled trials. Novel agents targeting Complement 5a have the potential to revolutionize the treatment of AAV. The aim of this curriculum is to educate clinicians on the most recent advances in the management of patients with AAV.
Supported by an independent educational grant from
Vifor Pharma
See All
Comparisons of guidelines and recommendations on managing antineutrophil cytoplasmic antibody-associated vasculitis
See All
Steering Committee Chair
Professor of Clinical Autoimmunity
University of Cambridge
Cambridge, United Kingdom
Department of Internal Medicine, Nephrology
Expert Center for Lupus- Vasculitis- and Complement-mediated Systemic Autoimmune Diseases
Leiden University Medical Center
Leiden, The Netherlands
Professor of Medicine
Cochin Hospital
Paris, France
Professor
General University Hospital
Charles University
Prague, Czech Republic
Associate Professor of Nephrology
University of Florence
Nephrology Unit
Meyer Children’s Hospital
Florence, Italy
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Chemocentryx; GlaxoSmithKline; InflaRx
Received grants for clinical research from: Chemocentryx; Roche Holdings AG/ Genentech, Inc.
Owns stock, stock options, or bonds from: Aurinia
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Aurinia Pharmaceuticals; GlaxoSmithKline; Novartis; Vifor Pharma
Received grants for clinical research from: Aurinia Pharmaceuticals; GlaxoSmithKline; Vifor Pharma
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Chugai; Grifols; LFB Biopharmaceuticals; Roche Holdings AG; Vifor Pharma
Served as a speaker or a member of a speakers bureau for: Grifols
Received grants for clinical research from: AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Vifor Pharma
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amgen Inc.; Calliditas; FMC; Retophin
Served as a speaker or a member of a speakers bureau for: AbbVie Inc.; Amgen Inc.; Novartis Pharmaceuticals Corporation
Has disclosed the following relevant financial relationships:
has disclosed no relevant financial relationships.